Cargando…

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab

The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn’s disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jauregui-Amezaga, Aranzazu, Somers, Michael, De Schepper, Heiko, Macken, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697448/
https://www.ncbi.nlm.nih.gov/pubmed/29180886
http://dx.doi.org/10.2147/CEG.S110546